TST8
New insights into the drivers and dynamics of HER2+/ER+ breast cancer response to targeted treatments
Analysis of molecular data from the NA-PHER2 trial, led by Fondazione Michelangelo researchers, identified new biomarkers predictive of response in HER2+/ER+ breast cancer patients receiving targeted treatments